Alpha 2.0
Login Register
» Journals » BMJ Oncol

Bmj Oncology

Bmj Oncology is a scientific journal, published since 2022 in English. The journal's country of origin is United Kingdom and its primary focus area is oncology.
Details
Abbr. BMJ Oncol
Start 2022
End Continuing
e-ISSN 2752-7948
Country United Kingdom
Language English
Specialty Oncology
Recent Articles
1.
Advancing cancer care through digital access in the USA: a state-of-the-art review of patient portals in oncology
Suresh U, Ancker J, Salmi L, Diamond L, Rosenbloom T, Steitz B
BMJ Oncol . 2025 Mar; 4(1):e000432. PMID: 40052188
Patient portal use among patients with cancer has increased significantly in recent years. This state-of-the-art review seeks to address and analyse literature involving patient portal use by patients with cancer...
2.
Predicting short-term risk of colorectal cancer using primary care records, genetics and lifestyle factors
Kartsonaki C
BMJ Oncol . 2025 Mar; 4(1):e000637. PMID: 40046833
No abstract available.
3.
Whole-body integral dose and post-radiotherapy lymphocytopaenia in solid tumours
Joseph N, Alagiyawanna L, Ruwanpura T, Gunasekera S, Ruvinda L, Madushan S, et al.
BMJ Oncol . 2025 Mar; 4(1):e000522. PMID: 40046832
Objective: Since modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) pivot on a strategy of dose redistribution, it may increase integral dose and consequently worsening of lymphocytopaenia. In this study,...
4.
Genetics, primary care records and lifestyle factors for short-term dynamic risk prediction of colorectal cancer: prospective study of asymptomatic and symptomatic UK Biobank participants
Ip S, Harrison H, Usher-Smith J, Barclay M, Tyrer J, Dennis J, et al.
BMJ Oncol . 2025 Mar; 4(1):e000336. PMID: 40046831
Objectives: To quantify the contributions of polygenic scores, primary care records (presenting symptoms, medical history and common blood tests) and lifestyle factors, for short-term risk prediction of colorectal cancer (CRC)...
5.
Patina of precision: risk models for lung cancer screening eligibility
Bach P, Mazer B
BMJ Oncol . 2025 Mar; 4(1):e000663. PMID: 40046830
No abstract available.
6.
UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results
Evans D, Burghel G, Schlecht H, Sachdeva A, Hudson A, Parikh O, et al.
BMJ Oncol . 2025 Mar; 4(1):e000592. PMID: 40046829
Objective: Germline pathogenic variants (PVs) are known to cause ~4% of prostate cancer, but other homologous repair genes, and Lynch syndrome genes are also involved. Our objective was to assess...
7.
Long-term outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer
Hassan H, Rahman T, Bacon A, Knott C, Allen I, Huntley C, et al.
BMJ Oncol . 2025 Mar; 4(1):e000574. PMID: 40046828
Objectives: To investigate the association between bilateral salpingo-oophorectomy (BSO) and long-term health outcomes in women with a personal history of breast cancer. Methods And Analysis: We used data on women...
8.
Evaluating the genetic landscape of prostate cancer: new insights from BRCA1/2, ATM and CDK12 mutations
Urabe F, Takemura K
BMJ Oncol . 2025 Mar; 4(1):e000717. PMID: 40046827
No abstract available.
9.
Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis
Sun H, Zhu X, Wang Z, Gao Q, Ji Y, Shi Y, et al.
BMJ Oncol . 2025 Mar; 3(1):e000578. PMID: 40046248
Objective: This phase Ib trial aimed to assess the safety and efficacy of sintilimab plus bevacizumab (sintilimab/bev), followed by resection in patients with potentially resectable intermediate-stage hepatocellular carcinoma (HCC) and...
10.
Six-year performance of risk-based selection for lung cancer screening in the Manchester Lung Health Check cohort
Goodley P, Balata H, Robbins H, Booton R, Sperrin M, Crosbie P
BMJ Oncol . 2025 Mar; 3(1):e000560. PMID: 40046247
Objective: Risk prediction models are used to determine eligibility for targeted lung cancer screening. However, prospective data regarding model performance in this setting are limited. Here we report the performance...